Skip to content

Study · Randomized controlled trial · 2009

6 results

Desmopressin, as a "designer-drug," in the treatment of overactive bladder syndrome.

Hashim H, Malmberg L, Graugaard-Jensen C, Abrams P

Neurourology and urodynamics1 Jan 2009Cited by 25 (Europe PMC)

PMID18726947 (opens in a new tab)DOI10.1002/nau.20613 (opens in a new tab)PepBankPUB-18726947
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with overactive bladder, desmopressin delayed the first void by 8 minutes versus placebo, without significance (P = 0.27).

    In plain wordsIn adults with overactive bladder, desmopressin delayed the first urination by 8 minutes versus placebo, without a significant difference.

    Peptide
    Desmopressin
    Outcome
    No significant changeTime to first void
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bladder Symptoms · Kidney and urinary
    Studied dose
    0.2 mg · oral · 2 weeksAs given in this study (human).

    Measurements

    Time to first void difference
    8 min
    desmopressin later than placebo
    P value
    0.27
    time to first void, desmopressin vs placebo

    Source sentences

    Summary
    Time to first void was 8-min later on the drug than on placebo (P = 0.27).
    2 context sentences
    Summary · context
    An investigator-initiated, 2-week, multi-national, multi-centre, "proof-of-concept," phase IIb, double-blind, placebo-controlled, prospective, randomized, cross-over study was conducted using 0.2 mg of oral desmopressin in adults suffering with OAB.
    Summary · context
    The primary endpoint was evaluation of effectiveness of desmopressin in increasing the time to the first OAB symptom episodes during the first 8-hr following treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with overactive bladder, desmopressin increased time to first urgency versus placebo (P < 0.003).

    In plain wordsIn adults with overactive bladder, desmopressin delayed the first urgent need to urinate compared with placebo.

    Peptide
    Desmopressin
    Outcome
    IncreaseTime to first urgency episode
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bladder Symptoms · Kidney and urinary
    Studied dose
    0.2 mg · oral · 2 weeksAs given in this study (human).

    Measurements

    P value
    < 0.003
    time to first urgency episode, desmopressin vs placebo

    Source sentences

    Summary
    There was an increase in the time to first urgency episode with a decrease in the number of urgency episodes in the drug days compared to placebo (P < 0.003).
    2 context sentences
    Summary · context
    An investigator-initiated, 2-week, multi-national, multi-centre, "proof-of-concept," phase IIb, double-blind, placebo-controlled, prospective, randomized, cross-over study was conducted using 0.2 mg of oral desmopressin in adults suffering with OAB.
    Summary · context
    The primary endpoint was evaluation of effectiveness of desmopressin in increasing the time to the first OAB symptom episodes during the first 8-hr following treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with overactive bladder, desmopressin reduced voids to 3.2 versus 4.2 with placebo (P < 0.001).

    In plain wordsIn adults with overactive bladder, desmopressin reduced urinations to 3.2 versus 4.2 with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseNumber of voids
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bladder Symptoms · Kidney and urinary
    Studied dose
    0.2 mg · oral · 2 weeksAs given in this study (human).

    Measurements

    Number of voids in first 8 hours
    3.2 voids
    desmopressin
    Number of voids in first 8 hours
    4.2 voids
    placebo
    P value
    < 0.001
    voids, desmopressin vs placebo

    Source sentences

    Summary
    However, the drug led to one less void (3.2 vs. 4.2) in the same period (P < 0.001).
    1 context sentence
    Summary · context
    An investigator-initiated, 2-week, multi-national, multi-centre, "proof-of-concept," phase IIb, double-blind, placebo-controlled, prospective, randomized, cross-over study was conducted using 0.2 mg of oral desmopressin in adults suffering with OAB.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with overactive bladder, desmopressin reduced urgency episodes versus placebo (P < 0.003).

    In plain wordsIn adults with overactive bladder, desmopressin reduced urgent needs to urinate compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseUrgency episodes
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bladder Symptoms · Kidney and urinary
    Studied dose
    0.2 mg · oral · 2 weeksAs given in this study (human).

    Measurements

    P value
    < 0.003
    number of urgency episodes, desmopressin vs placebo

    Source sentences

    Summary
    There was an increase in the time to first urgency episode with a decrease in the number of urgency episodes in the drug days compared to placebo (P < 0.003).
    1 context sentence
    Summary · context
    An investigator-initiated, 2-week, multi-national, multi-centre, "proof-of-concept," phase IIb, double-blind, placebo-controlled, prospective, randomized, cross-over study was conducted using 0.2 mg of oral desmopressin in adults suffering with OAB.
  5. 05HumanNon-randomized trialEfficacy outcome

    In adults with overactive bladder, the abstract reported subjective improvement in frequency, urgency and overall quality of life on ICIQ-OAB.

    In plain wordsIn adults with overactive bladder, the study reported subjective improvement in urinary symptoms and quality of life.

    Peptide
    Desmopressin
    Outcome
    Direction not reportedSubjective frequency, urgency and quality of life
    Study

    n: not reported in source

    Outcome group
    Bladder Symptoms · Kidney and urinary
    Studied dose
    0.2 mg · oral · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    There was a subjective improvement in frequency and urgency and overall quality-of-life as measured by the ICIQ-OAB.
    1 context sentence
    Summary · context
    An investigator-initiated, 2-week, multi-national, multi-centre, "proof-of-concept," phase IIb, double-blind, placebo-controlled, prospective, randomized, cross-over study was conducted using 0.2 mg of oral desmopressin in adults suffering with OAB.
  6. 06HumanNon-randomized trialSafety outcome

    In the overactive bladder study of desmopressin, no hyponatremia was recorded.

    In plain wordsIn the overactive bladder study of desmopressin, no low blood sodium was recorded.

    Peptide
    Desmopressin
    Outcome
    Not applicableHyponatremia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    0.2 mg · oral · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Twenty-seven people reported adverse events which were all mild, headache being the commonest and no hyponatremia was recorded.
    1 context sentence
    Summary · context
    An investigator-initiated, 2-week, multi-national, multi-centre, "proof-of-concept," phase IIb, double-blind, placebo-controlled, prospective, randomized, cross-over study was conducted using 0.2 mg of oral desmopressin in adults suffering with OAB.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.